Tarsus director awarded options and RSUs

Tarsus Pharmaceuticals director William J. Link, PhD reported equity awards tied to his service as a non-employee director as of the company’s 2026 annual meeting of stockholders.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals director William J. Link, PhD reported equity awards tied to his service as a non-employee director as of the company’s 2026 annual meeting of stockholders. He received grants of restricted stock units and stock options that provide future rights to Tarsus common shares.

The filing shows 3,837 stock options with an exercise price of $64.34 per share, vesting in full on the one-year anniversary of the grant date and expiring on June 24, 2036, subject to continued service. It also reports RSU awards covering 806 and 2,417 shares, with one grant vesting in full after one year and the other vesting in four equal installments from September 15, 2026 through June 15, 2027.

Insider Trade Summary

Grant/Award: 7,060 shares

Grant/Award 3 txns

Insider LINK WILLIAM J PHD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	3,837	$0.00	$0.00
Grant/Award	Restricted Stock Units	2,417	$0.00	$0.00
Grant/Award	Restricted Stock Units	806	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 3,837 contracts (Direct); Restricted Stock Units — 3,223 contracts (Direct)

Footnotes (4)

1. F1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
2. F2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
4. F4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Key Figures

Stock options granted: 3,837 shares Option exercise price: $64.34 per share Option expiration: June 24, 2036 +2 more

5 metrics

Stock options granted 3,837 shares Annual non-employee director option grant at $64.34 exercise price

Option exercise price $64.34 per share Stock Option (right to buy) granted June 25, 2026

Option expiration June 24, 2036 Expiration date for 3,837-share stock option award

RSU grant 1 size 806 RSUs Vests in full on one-year anniversary of grant

RSU grant 2 size 2,417 RSUs Vests in four installments on 9/15/2026, 12/15/2026, 3/15/2027, 6/15/2027

Key Terms

Restricted Stock Unit, Stock Option (right to buy), non-employee director, vesting

4 terms

Restricted Stock Unit financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock."

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of 64.3400 and expiration date of 2036-06-24."

non-employee director financial

"Granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders."

vesting financial

"The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Tarsus (TARS) director William J. Link receive?

William J. Link, PhD received stock options for 3,837 shares at $64.34 and RSU grants covering 806 and 2,417 shares. These awards are compensation for his service as a non-employee director at Tarsus Pharmaceuticals.

How do the new RSUs for Tarsus (TARS) director William J. Link vest?

One RSU grant of 806 units vests in full on the one-year anniversary of grant. The 2,417-unit RSU grant vests in four equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to continuous board service.

What are the key terms of William J. Link’s new Tarsus (TARS) stock options?

The annual stock option grant covers 3,837 shares of Tarsus common stock at a $64.34 exercise price. It will vest in full on the one-year anniversary of the grant date and expires on June 24, 2036, assuming continued director service.

Are William J. Link’s Form 4 transactions in Tarsus (TARS) shares open-market buys or sales?

The reported transactions are equity compensation grants, not open-market trades. All three entries are coded as awards (transaction code A), covering stock options and restricted stock units granted for his non-employee director service at Tarsus Pharmaceuticals.

What does each Restricted Stock Unit represent for Tarsus (TARS) director William J. Link?

Each RSU represents a contingent right to receive one share of Tarsus common stock. Shares are delivered only as units vest under the specified schedules, and vesting is conditioned on William J. Link’s continuous service as a non-employee director.

Why did Tarsus (TARS) grant equity awards at the 2026 annual meeting?

The stock option and RSU grants were made in connection with William J. Link’s service as a non-employee director as of Tarsus’s 2026 annual meeting. Such annual equity grants are a common form of board compensation aligned with shareholder interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/29/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINK WILLIAM J PHD

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

17700 LAGUNA CANYON ROAD, FLOOR 4

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$64.34	06/25/2026		A		3,837		(1)	06/24/2036	Common Stock	3,837	$0	3,837	D
Restricted Stock Units	(2)	06/25/2026		A		2,417		(3)	(3)	Common Stock	2,417	$0	2,417	D
Restricted Stock Units	(2)	06/25/2026		A		806		(4)	(4)	Common Stock	806	$0	806	D

Explanation of Responses:

1. Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

4. RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Remarks:

	/s/ Scott Sieckert, Attorney-in-Fact	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)